United States Patent 9,533,955 (bendamustine HCl Form 3): Claim scope, crystal-definition boundaries, and US patent landscape for generics and formulations
US Patent 9,533,955 is a solid-state IP asset that claims a specific crystalline polymorph of bendamustine hydrochloride designated “Form 3” by X-ray powder diffraction (XRPD) peak positions, plus formulation compositions and methods of treatment using that Form 3 material. The independent claim center of gravity is the XRPD signature (not particle size, not a manufacturing step), which creates a direct validity and infringement hinge for any competitor attempting to commercialize a different polymorph or a Form 3 material whose XRPD peaks do not match the claimed tolerance.
What exactly does US 9,533,955 claim: Form 3 defined by XRPD peaks?
Core concept. The patent defines a “crystalline form of bendamustine hydrochloride that is Form 3” using an XRPD peak set anchored at 2θ = 7.9 and 15.5 ± 0.2 degrees 2θ, with optional dependent fallbacks adding additional peak candidates.
Claim 1: the polymorph definition (independent)
Claim 1 covers:
- A crystalline form of bendamustine hydrochloride that is Form 3
- Producing an XRPD pattern having peaks at:
Scope boundary.
- “Form 3” is not defined by a structural descriptor in the claim text you provided. It is operationally defined by the XRPD peak positions.
- The claim is silent on:
- whether peaks must be intense above a threshold,
- whether the XRPD must be measured under a specific instrument setting, temperature, or sample prep conditions,
- whether other peaks may exist (the claim only requires the stated peaks).
Claim 2: optional additional XRPD peaks (dependent)
Claim 2 narrows Form 3 to XRPD patterns that further comprise a peak selected from:
- 10.6
- 21.3
- 22.1
- 23.3
- 26.1 ± 0.2 degrees 2θ
Scope boundary.
- This is not a full listing of all peaks; it is a dependent “further comprises” limitation with a selectable peak from a group.
Claims 3-9: formulation compositions containing Form 3 (crystal + excipient)
Claim 3 covers:
- A composition comprising:
- at least one pharmaceutically acceptable excipient
- and crystalline bendamustine HCl Form 3
- where the composition produces an XRPD pattern with peaks at:
Claim 4 adds the same optional XRPD peak-group limitation as Claim 2.
Claim 5: excipient genus limitation (dependent)
Claim 5 restricts the excipient to a listed group including:
- sodium phosphate, potassium phosphate
- citric acid, tartaric acid
- gelatin, glycine
- mannitol
- lactose, sucrose, maltose
- glycerin, dextrose, dextran
- trehalose
- hetastarch
- or mixtures thereof
Claim 6: mannitol specifically (dependent)
Claim 6 narrows Claim 3/5 to:
Claims 7-9: mixture state limitations (dependent)
These depend on Claim 3:
- Claim 7: composition further comprising bendamustine HCl monohydrate
- Claim 8: composition further comprising amorphous bendamustine HCl
- Claim 9: composition further comprising both monohydrate and amorphous
Scope boundary.
- These claims contemplate formulations where Form 3 exists alongside other solid states. That matters for infringement analysis because a competitor could try to evade by producing a polymorph mixture. The patent does not require Form 3 as the sole solid phase; it requires the XRPD peaks for Form 3 to be present in the measured pattern of the composition.
Claims 10-12: methods of treatment and administration format
Claim 10 covers methods of treating:
- chronic lymphocytic leukemia
- Hodgkin’s disease
- non-Hodgkin’s lymphoma
- multiple myeloma
- breast cancer
by administering a composition according to Claim 3.
Claim 11 narrows:
- non-Hodgkin’s lymphoma = indolent B-cell non-Hodgkin’s lymphoma
Claim 12 narrows:
- administration as a reconstituted injectable preparation
Scope boundary.
- The treatment claims are tethered directly to the claimed composition (Claim 3). If a competitor avoids Claim 3 by not using Form 3 material, these method claims typically collapse unless there is a separate inventive feature.
- The claims do not specify a dose regimen, route beyond “reconstituted injectable preparation,” or a specific concentration.
What XRPD “7.9° and 15.5 ± 0.2°” means for infringement risk
For polymorph patents that rely on XRPD peak positions, the practical infringement question becomes whether a commercial material or final drug product, when tested under relevant conditions, shows the required peaks within the tolerances.
Claim 1 infringement hinge: are the peaks present at the required positions?
- “7.9 degrees 2θ” appears as a single-point requirement. The claim text you provided does not include an explicit tolerance for 7.9. A practical infringement dispute will turn on whether competitor testing uses a convention that effectively introduces measurement uncertainty, and whether courts treat the “peak at 7.9” as requiring a narrow match or allowing some shift.
- “15.5 ± 0.2 degrees 2θ” gives an explicit band from 15.3 to 15.7° 2θ.
Claim 2/4 infringement hinge: additional selectable peak
Claim 2 requires “further comprises” one of the listed additional peaks. This gives a dependent narrowing but also creates a path for proving infringement even if some other minor peaks differ.
Formulation claims add “XRPD pattern” requirement to the composition itself
Claims 3 and 4 require that the composition “produces an XRPD pattern” with the Form 3 peak positions. That expands infringement to situations where Form 3 is present in the formulated product and remains detectable by XRPD.
What the claims do not cover (key design-around themes)
Based strictly on the claim text:
- No coverage is claimed for:
- bendamustine Form 1 or Form 2 polymorphs
- a different crystalline signature that lacks both the anchor peaks
- different defining characterization metrics (DSC, solid-state IR, Raman, particle size distribution) as standalone limitations
- No manufacturing method steps are claimed.
- No chemical composition change is required beyond “bendamustine hydrochloride” crystalline Form 3.
Design-around strategy for generic/formulation developers typically targets the solid-state identity (polymorph) or the XRPD detectability in the final composition.
How broad is the excipient coverage in Claims 3-6?
The excipient set in Claim 5 is a defined list, including multiple common pharmaceutical excipients, with an explicit spotlight on:
- phosphate buffers (sodium/potassium phosphate)
- acids (citric/tartaric)
- stabilizers/sugars (mannitol, lactose, sucrose, maltose, trehalose)
- polymers/biocolloids (gelatin, dextran, hetastarch)
- glycerin and dextrose
Claim 6 narrows to mannitol. From a freedom-to-operate perspective:
- A product formulated with a listed excipient can still be within the patent if it contains Form 3 meeting the XRPD signature.
- A product using a non-listed excipient could attempt to avoid Claims 5-6 while still risking independent Claim 3 if it still uses Form 3 with the signature peaks and has at least one pharmaceutically acceptable excipient.
Methods-of-use claims: what do they add beyond formulation coverage?
The method claims (10-12) do not add a new formulation limitation beyond tethering to Claim 3. They add:
- treatment indications across major bendamustine use areas
- a narrowing to indolent B-cell NHL
- administration as reconstituted injectable preparation
In practice, these method claims primarily matter if a competitor would otherwise dispute:
- whether its product is “a composition according to claim 3,” or
- whether the product is made for or used in the claimed indication set and admin format.
US patent landscape context: how 9,533,955 typically fits into a polymorph estate
Based on the claim style (polymorph + XRPD identity + formulation + clinical use), US 9,533,955 usually sits within a broader “solid form” and “drug product stability” patent strategy around bendamustine hydrochloride. In these estates, adjacent patents often include:
- other polymorph/crystal forms designated Form 1/Form 2/Form 3
- amorphous forms or solid-state mixtures
- manufacturing-related crystal formation steps
- lyophilized or reconstituted injectable compositions with specific stabilizers
- analytical methods for confirming solid state
However, without the rest of your provided record (e.g., the patent’s full title/assignee, prosecution history, and the full US family list), a complete cross-patent mapping cannot be produced here without risking false precision.
Competitive and regulatory implications (high-level, tied to claim structure)
Paragraph IV / FDA generic entry risk profile
For an ANDA filer targeting a bendamustine HCl injectable, the key question is whether the proposed generic product:
- contains the same polymorph (Form 3) that meets the XRPD signature, and
- uses an excipient system that overlaps with Claims 5-6 (mannitol and phosphate/acid excipients), and
- is tested such that XRPD demonstrates the required peaks at the required positions.
Because the independent claim is XRPD-anchored, competitors cannot rely solely on avoiding a named excipient once Claim 3’s “at least one pharmaceutically acceptable excipient” is considered.
Potential biosimilar risk
Bendamustine is a small molecule; biosimilar frameworks do not apply. The relevant competitive threat is standard generic substitution.
Litigation leverage
Polymorph patents with XRPD peaks often concentrate disputes on:
- comparative XRPD test methods,
- peak assignment and instrument conditions,
- whether the competitor’s solid form is the claimed polymorph or a different form with overlapping peaks,
- whether formulation processing converts polymorphs (polymorphic transformation during manufacture or storage).
These disputes are structurally driven by the claim’s “produces an XRPD pattern having peaks at…” language.
Summary table: claim-by-claim scope for US 9,533,955
| Claim |
What is covered |
Key limitations (as provided) |
Practical impact |
| 1 |
Crystal polymorph |
Bendamustine HCl crystalline “Form 3” with XRPD peaks at 7.9° and 15.5 ± 0.2° 2θ |
Core infringement hinge: Form 3 identity by XRPD |
| 2 |
Polymorph + extra peak |
Adds a further XRPD peak selected from 10.6, 21.3, 22.1, 23.3, 26.1 ± 0.2° |
Dependent narrowing but still supports infringement with partial peak sets |
| 3 |
Drug product composition |
Form 3 crystal + excipient; XRPD peaks 7.9° and 15.5 ± 0.2° |
Covers formulated products if Form 3 signature remains detectable |
| 4 |
Composition + extra peak |
Adds further XRPD peak selected from same set as Claim 2 |
Dependent narrowing |
| 5 |
Composition excipient genus |
Excipient is one of listed excipients (incl. phosphates, citric/tartaric, gelatin, glycine, mannitol, sugars, dextran, trehalose, hetastarch) |
Narrows formulation excipient set |
| 6 |
Composition excipient specific |
Excipient = mannitol |
Highlights mannitol-based products |
| 7 |
Composition with other solid states |
Adds monohydrate to Claim 3 composition |
Blocks simple “mixture escape” if Form 3 peaks persist |
| 8 |
Composition with other solid states |
Adds amorphous to Claim 3 |
Same: mixture still captured if Form 3 peaks exist |
| 9 |
Composition with other solid states |
Adds both monohydrate and amorphous |
Same |
| 10 |
Methods of treating diseases |
Administer Claim 3 composition for specified cancers |
Use claims tied to Claim 3 |
| 11 |
Indolent B-cell NHL |
NHL = indolent B-cell |
Narrower indication |
| 12 |
Dosage/form |
Reconstituted injectable preparation |
Narrows admin format |
Key takeaways
- US 9,533,955 is primarily a solid-state polymorph patent: Form 3 of bendamustine hydrochloride is defined by an XRPD signature requiring peaks at 7.9° and 15.5 ± 0.2° 2θ.
- The formulation claims extend coverage to drug product compositions where those Form 3 peaks remain detectable in the XRPD pattern of the composition, even when mixed with monohydrate and/or amorphous solids.
- The excipient claims are important for dependent narrowing (notably mannitol), but the broadest independent formulation claim requires only “at least one pharmaceutically acceptable excipient,” so excipient swaps do not guarantee freedom-to-operate if the crystalline Form 3 XRPD signature is present.
- The method-of-use claims add indication and injectable reconstitution framing but are tethered to administering a composition that falls within Claim 3.
FAQs
-
How can a generic avoid infringement if it uses bendamustine hydrochloride but not the same polymorph?
By ensuring the marketed API and final drug product do not produce an XRPD pattern matching the required Form 3 peaks at 7.9° and 15.5 ± 0.2° 2θ.
-
Do Claims 7-9 let competitors include amorphous or monohydrate to avoid the patent?
Not if Form 3 XRPD peaks persist in the composition. The dependent claims contemplate mixtures that still remain within the patent if the Form 3 signature is present.
-
Does changing the excipient from mannitol eliminate risk under Claim 6?
It may avoid Claim 6, but it does not avoid Claim 3 if the composition still meets the XRPD Form 3 signature and contains any pharmaceutically acceptable excipient.
-
What XRPD element is most likely to be litigated in claim charts for this patent?
Peak matching and measurement tolerances for the anchor peaks, especially the 15.5 ± 0.2° band and the “peak at 7.9°” requirement without an explicit tolerance.
-
Are the method claims (10-12) broader than the formulation claims?
No. They are limited by administering a composition that satisfies Claim 3, so the formulation’s XRPD-defined scope drives method claim exposure.
References (APA)
- United States Patent 9,533,955. Claims text as provided by user.
